Provided by Tiger Fintech (Singapore) Pte. Ltd.

Arvinas Holding Company LLC

7.53
+0.61008.82%
Post-market: 7.570.0400+0.53%18:56 EDT
Volume:2.76M
Turnover:20.46M
Market Cap:549.63M
PE:-11.65
High:7.58
Open:7.05
Low:7.05
Close:6.92
Loading ...

Arvinas Inc. Announces Resignation of R&D President Ian Taylor, Ph.D.; Enters Into Consulting Agreement

Reuters
·
5 hours ago

Sector Update: Health Care Stocks Advance Premarket Friday

MT Newswires Live
·
Yesterday

Arvinas and Pfizer Submit NDA for Vepdegestrant to FDA for Treatment of ESR1-Mutated ER+/HER2- Advanced Breast Cancer

Reuters
·
Yesterday

Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients With Esr1-Mutated Er+/Her2- Advanced or Metastatic Breast Cancer

THOMSON REUTERS
·
Yesterday

Arvinas Inc. to Present Promising Preclinical Data for PROTAC BCL6 Degrader ARV-393 at 2025 EHA Annual Meeting

Reuters
·
05 Jun

BUZZ-U.S. STOCKS ON THE MOVE-Natgas companies, UnitedHealth, Cactus

Reuters
·
03 Jun

Arvinas-Pfizer partnership dynamics may shift, says H.C. Wainwright

TIPRANKS
·
02 Jun

BUZZ-Arvinas falls after Leerink downgrades

Reuters
·
02 Jun

Arvinas Cut to Market Perform From Outperform by Leerink Partners

Dow Jones
·
02 Jun

Arvinas Holding Company (ARVN) Receives a Hold from Truist Financial

TIPRANKS
·
02 Jun

Arvinas Shares Sink After Breast Cancer Treatment Didn't Improve Survival in Intent-to-Treat Population

Dow Jones
·
02 Jun

Arvinas Inc : Leerink Partners Cuts to Market Perform From Outperform; Cuts Target Price to$ 9 From $10

THOMSON REUTERS
·
02 Jun

Piper Sandler Sticks to Its Buy Rating for Arvinas Holding Company (ARVN)

TIPRANKS
·
02 Jun

Arvinas Holding Company (ARVN) Gets a Buy from Barclays

TIPRANKS
·
02 Jun

Arvinas downgraded to Market Perform from Outperform at Leerink

TIPRANKS
·
02 Jun

Arvinas, Pfizer announce VERITAC-2 trial did not reach statistical significance

TIPRANKS
·
02 Jun

Arvinas Inc - Vepdegestrant First Protac to Show Benefit in Breast Cancer

THOMSON REUTERS
·
31 May

Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients With Esr1-Mutant, Er+/Her2- Advanced Breast Cancer

THOMSON REUTERS
·
31 May

Arvinas Inc - Nda for Vepdegestrant to Be Submitted to FDA in Second Half of 2025

THOMSON REUTERS
·
31 May

Arvinas Inc - Vepdegestrant Well Tolerated With Low Gi Adverse Events

THOMSON REUTERS
·
31 May